Physician profile
Jeffrey Egan Wold
NPI 1679658801
$957.55
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.08 · 2020: $725 · 2021: $139 · 2022: $11.86 · 2023: $9.63 · 2024: $60.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| A-Dec, INC. | $635.00 | 2020 | |
| Align Technology, INC. | $227.40 | 2020-2023 | Itero Element 5d Plus |
| Solventum Corporation | $60.75 | 2024 | 3m Scotchbond, 3m Relyx |
| Philips North America LLC | $23.32 | 2021-2022 | |
| Elevate Oral Care | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.